Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
02 oct. 2023 01h15 HE
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Phase III APPLAUSE-IgAN study met its pre-specified interim analysis primary endpoint, demonstrating superiority of iptacopan vs placebo in proteinuria...
Novartis completes divestment of ‘front of eye’ ophthalmology assets
29 sept. 2023 10h00 HE
|
Novartis Pharma AG
Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapiesNovartis advances strategy of focused portfolio and prioritized therapeutic...
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
26 sept. 2023 01h15 HE
|
Novartis Pharma AG
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from...
Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
25 sept. 2023 01h17 HE
|
Novartis Pharma AG
Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced...
Novartis confirms Sandoz Spin-off for October 4, 2023
25 sept. 2023 01h15 HE
|
Novartis Pharma AG
Sandoz shares (SDZ) to be listed and traded on SIX Swiss Exchange; ADRs to be traded on OTCQX®, first trading day October 4, 2023Sandoz to be included in key Swiss market indicesInvestment grade...
Sandoz receives positive CHMP opinion for breast and gastric cancer biosimilar trastuzumab
18 sept. 2023 01h15 HE
|
Novartis Pharma AG
Positive CHMP opinion based on comprehensive package of analytical, pre-clinical and clinical dataBreast and gastric cancers are among most common types of cancer, accounting together for nearly half...
Aktionärinnen und Aktionäre von Novartis stimmen dem geplanten 100% igen Spin-off von Sandoz zu
15 sept. 2023 05h36 HE
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer...
Les actionnaires de Novartis approuvent le projet de scission à 100% de Sandoz
15 sept. 2023 05h36 HE
|
Novartis Pharma AG
Les actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le...
Novartis shareholders approve the proposed 100% Spin-off of Sandoz
15 sept. 2023 05h36 HE
|
Novartis Pharma AG
Shareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off...
Sandoz announces exclusive deal to commercialize biosimilar ustekinumab, further reinforcing growing pipeline and immunology patient offering
11 sept. 2023 01h15 HE
|
Novartis Pharma AG
Agreement with Samsung Bioepis gives Sandoz exclusive commercialization rights to biosimilar SB17 ustekinumab in Europe and North AmericaUstekinumab is a fully human monoclonal antibody to interleukin...